Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous gene-modified PD-1-positive T lymphocytes Sc610

A preparation of autologous programmed cell death protein 1 (PD-1; PDCD1; CD279)-positive T lymphocytes transduced with a lentiviral vector encoding for an as of yet undisclosed receptor, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous gene-modified PD-1-positive T lymphocytes Sc610 bind to tumor cells expressing the antigen for the as of yet undisclosed receptor, which may result in specific cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous gene-modified PD-1-positive T cells Sc610
Code name:	Sc 610 Sc-610 Sc610

autologous gene-modified PD-1-positive T lymphocytes Sc610

Search NCI's Drug Dictionary